Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

Maintenance Therapies in Late-Life Depression 2 (MTLD-2)

This study will evaluate the effectiveness of paroxetine versus interpersonal psychotherapy and a combination of the two in helping elderly patients with depression remain well and improve quality of their lives.

This is primarily a study of maintenance therapies, not a study of acute therapeutic efficacy, in late-life major depression. The study aims to identify factors that encourage maintenance of treatment gains and to identify which patients need which kinds of treatment to remain well. The following questions are to be addressed:

• Is the probability of recurrence different among the treatment groups?
• What variables may be related to, or predictive of, differences among groups?
• After 1 to 2 years of maintenance therapy, will patients assigned to maintenance combined treatment with both paroxetine and interpersonal psychotherapy remain well at higher rates than patients assigned to paroxetine alone, interpersonal psychotherapy alone, or placebo?
• Will the time to recurrence differ across treatment groups, and what variables may be related to, or predictive of, time to recurrence?

The major study hypothesis is that combined treatment with paroxetine and interpersonal psychotherapy will be superior to either treatment alone (and to placebo) in preventing recurrence of major depressive episodes in patients aged 70 and above.

For information on related studies, please follow these links:

http://clinicaltrials.gov/show/NCT00000377

http://clinicaltrials.gov/show/NCT00177671

Inclusion Criteria:

• Age 69 or older
• meets DSM-IV criteria for current unipolar major depression
• HRSD (17 item) score of 15 or higher
• Folstein Mini Mental Status exam score of 18 or higher

Exclusion Criteria:

• Lifetime diagnosis of any psychotic disorder or bipolar disorder
• alcohol or drug abuse within the past six months
• MATTIS Dementia Rating Score of 120 or less
• Contraindication to SSRI therapy
• Hyponatremia